Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms252011093 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Kana Kusaba und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japa…. Hauptthemen laut MEDLINE: Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib Mesylate, Oxidative Phosphorylation, Neoplastic Stem Cells. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bristol-Myers-Squibb, Pfizer, Ohara Pharmaceuticals.
Abstract (Originalsprache)
Patients with chronic myeloid leukemia (CML) respond to tyrosine kinase inhibitors (TKIs); however, CML leukemic stem cells (LSCs) exhibit BCR::ABL kinase-independent growth and are insensitive to TKIs, leading to disease relapse. To prevent this, new therapies targeting CML-LSCs are needed. Rates of mitochondria-mediated oxidative phosphorylation (OXPHOS) in CD34+CML cells within the primitive CML cell population are higher than those in normal undifferentiated hematopoietic cells; therefore, the inhibition of OXPHOS in CML-LSCs may be a potential cure for CML. NK-128 (C33H61NO5S) is a structurally simplified analog of JCI-20679, the design of which was based on annonaceous acetogenins. NK-128 exhibits antitumor activity against glioblastoma and human colon cancer cells by inhibiting OXPHOS and activating AMP-activated protein kinase (AMPK). Here, we demonstrate that NK-128 effectively suppresses the growth of CML cell lines and that the combination of imatinib and NK-128 is more potent than either alone in a CML xenograft mouse model. We also found that NK-128 inhibits colony formation by CD34+ CML cells isolated from the bone marrow of untreated CML patients. Taken together, these findings suggest that targeting OXPHOS is a beneficial approach to eliminating CML-LSCs, and may improve the treatment of CML.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
- Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga 849-8501, Japan.
- Clinical Research Center, Saga Medical School Hospital, Saga 849-8501, Japan.
- Faculty of Pharmaceutical Sciences, Nagasaki International University, Nagasaki 859-3298, Japan.
- Laboratory of Clinical Oncology, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan.
ORCID-Profile: Naoto Kojima
Förderung
- Bristol-Myers-Squibb
- Pfizer
- Ohara Pharmaceuticals
Zitieren
APA
Kusaba, K., Watanabe, T., Kidoguchi, K., Yamamoto, Y., Tomoda, A., Hoshiko, T., Kojima, N., Nakata, S., & Kimura, S. (2024). Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms252011093
Vancouver
Kusaba K, Watanabe T, Kidoguchi K, Yamamoto Y, Tomoda A, Hoshiko T, et al. Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms252011093
BibTeX
@article{Kusaba2024,
author = {Kusaba, Kana and Watanabe, Tatsuro and Kidoguchi, Keisuke and Yamamoto, Yuta and Tomoda, Ayaka and Hoshiko, Toshimi and Kojima, Naoto and Nakata, Susumu and Kimura, Shinya},
title = {Targeting Oxidative Phosphorylation with a Novel Thiophene Carboxamide Increases the Efficacy of Imatinib against Leukemic Stem Cells in Chronic Myeloid Leukemia},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms252011093}
}
EUVIMED